Full Text View
Tabular View
No Study Results Posted
Related Studies
Open Label Extension Study in Patients With Idiopathic Pulmonary Fibrosis Who Completed Protocol AC-052-321/ BUILD 3 (BUILD OL)
This study is enrolling participants by invitation only.
First Received: February 12, 2008   Last Updated: October 14, 2009   History of Changes
Sponsor: Actelion
Information provided by: Actelion
ClinicalTrials.gov Identifier: NCT00631475
  Purpose

This Open-label extension study in patients with Idiopathic Pulmonary Fibrosis who completed protocol AC-052-321 / BUILD 3 will asses the long term safety and tolerability of bosentan in patients with idiopathic pulmonary fibrosis (IPF).


Condition Intervention Phase
Idiopathic Pulmonary Fibrosis
Drug: Bosentan
Phase III

Study Type: Interventional
Study Design: Treatment, Non-Randomized, Open Label, Single Group Assignment, Safety Study
Official Title: Open-Label Extension Study in Patients With Idiopathic Pulmonary Fibrosis Who Completed Protocol AC-052-321

Resource links provided by NLM:


Further study details as provided by Actelion:

Primary Outcome Measures:
  • Asses the long term safety and tolerability of bosentan in patients with idiopathic pulmonary fibrosis (IPF) [ Time Frame: Start of study to end of study ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • AE's leading to discontinuation of study drug [ Time Frame: end of study ] [ Designated as safety issue: Yes ]
  • Treatment-emergent SAE's [ Time Frame: up to 28 days after the end of study drug ] [ Designated as safety issue: Yes ]
  • Occurrence of LFT (ALT and AST) abnormality [ Time Frame: up to 24 hours after the end of study treatment ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 600
Study Start Date: March 2008
Estimated Primary Completion Date: March 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
1: Experimental

For patients who were administered bosentan during BUILD 3:

Same dose will continue

For patients who were administered placebo during BUILD 3:

Initial dose: 62.5 mg for 4 weeks Maintenance dose: 125 mg

Drug: Bosentan

For patients who were administered Bosentan during BUILD 3:

continue on same dose

For patients who were administered placebo during BUILD 3:

Oral Bosentan 62.5 mg for 4 weeks; maintenance dose: 125 mg ( 62.5 if patient weighs < 90 lbs.)


  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Patients should have completed all the assessments from the BUILD 3 EOS visit.

  • Signed informed consent prior to initiation of any study-related procedures.
  • Women of childbearing potential must have a negative serum pregnancy test and use reliable methods of contraception during study treatment and for 3 months after study treatment termination.

Exclusion Criteria:

  • Any major violation of protocol AC-052-321 / BUILD 3.
  • Pregnancy or breast-feeding.
  • AST and/or ALT > 3 times the upper limit of the normal range.
  • Any known factor or disease that might interfere with treatment compliance, study conduct or interpretation of the results, such as drug or alcohol dependence or psychiatric disease.
  • Known hypersensitivity to bosentan or any of the excipients.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00631475

  Hide Study Locations
Locations
United States, Alabama
UAB Division of Pulmonary
Birmingham, Alabama, United States, 35294
United States, Arizona
Mayo Clinic
Scottsdale, Arizona, United States, 85259
Pulmonary Associates
Phoenix, Arizona, United States, 85006
United States, California
UCLA- Division of Pulmonary & Critcal Care
Los Angeles, California, United States, 90095
Pulmoary and Critical Care Medicine-Stanford University Medical Center
Stanford, California, United States, 94305
UCSD Medical Center
San Diego, California, United States, 92103
USCF-Interstitial Lung Disease Center
San Francisco, California, United States, 94143
UC Davis University of California
Sacramento, California, United States, 95817
United States, Colorado
National Jewish Medical & Research Center
Denver, Colorado, United States, 80206
United States, Connecticut
Yale University School of Medicine
New Haven, Connecticut, United States, 06520
United States, Florida
PAB Clinical Research
Brandon, Florida, United States, 33511
United States, Georgia
Emory University
Atlanta, Georgia, United States, 30322
United States, Illinois
University of Chicago
Chicago, Illinois, United States
United States, Kansas
Wichita Clinic, P.A.
Wichita, Kansas, United States, 67208
Consultants in Pulmonary Medicine
Olathe, Kansas, United States, 66061
United States, Massachusetts
Boston University School of Medicine
Boston, Massachusetts, United States, 02118
Beth Israel Deaconness Medical Center
Boston, Massachusetts, United States, 02215
United States, Minnesota
Mayo Clinic
Rochester, Minnesota, United States, 55905
University of Minnesota
Minneapolis, Minnesota, United States, 55455
United States, Missouri
St. Luke's Medical Group, Cardio-Pulmonary Research
Chesterfield, Missouri, United States, 63017
United States, New Jersey
Pulmonary & Allergy Associates PA
Summit, New Jersey, United States, 07901
United States, New York
Highland Hospital - Pulmonary Department
Rochester, New York, United States, 14602
Mount Sinai School of Medicine
New York, New York, United States, 10029-6574
United States, North Carolina
Duke University-ID/Pulmonary Research-Park garage 2; Room 0002
Durham, North Carolina, United States, 27710
United States, Ohio
University of Cinicinnati
Cincinnati, Ohio, United States, 45267
The Cleveland Clinic Foundation
Cleveland, Ohio, United States, 44195
United States, Pennsylvania
Temple University
Philadelphia, Pennsylvania, United States, 19140
University of Pennsylvania Medical Center
Philadelphia, Pennsylvania, United States, 19104
United States, South Carolina
Medical University of South Carolina
Charleston, South Carolina, United States, 29425
United States, Tennessee
Vanderbilt Medical Center- IPF Center
Nashville, Tennessee, United States, 37232
United States, Texas
University of Texas-Southwestern Dallas-Div of Pulm & Critical Care Unit
Dallas, Texas, United States, 75390
Baylor College of Medicine
Houston, Texas, United States, 77030
United States, Utah
University of Utah
Salt Lake City, Utah, United States, 84108
United States, Vermont
Vermont Lung Center
Colchester, Vermont, United States, 05446
United States, Virginia
Inova Heart and Vascular Institute
Falls Church, Virginia, United States, 22042
University of Virginia - Division of Pulmonary and Critical Care
Charlottesville, Virginia, United States
United States, Washington
University of Washington Medical Center
Seattle, Washington, United States, 98195
United States, Wisconsin
University of Wisconsin-Madison
Madison, Wisconsin, United States, 53792-3240
Australia, New South Wales
St. Vincent's Public Hospital, Lung Transplantation & Respiratory Medicine
Darlinghurst, New South Wales, Australia, 2010
Australia, Queensland
Prince Charles Hospital- Lung Transplant, Thoraic Dept.
Chermside, Queensland, Australia, 4032
Australia, South Australia
Royal Adelaide Hospital-Respiratory Clinical Trials Unit
Adelaide, South Australia, Australia, 5000
Australia, Western Australia
Royal Perth Haspital; Advanced Lung Disease Unit
Perth, Western Australia, Australia, 6000
Austria
Medical University of Vienna and AKH-Div of Pulmonology
Wien, Austria, 1090
Medical University of Innsbruck-Dic of Clinical & Internal Medicine
Innsbruck, Austria, 6020
Landesklinikum Thermenregion Hochegg
Grimmenstein, Austria, 2840
Belgium
UZ Gasthuisberg
Leuven, Belgium, 3000
Canada, Alberta
Walter C. Mackenzie Health Sciences Centre-University of Alberta
Edmonton, Alberta, Canada, T6G 2B7
Canada, British Columbia
St. Paul's Hospital - Pacific Lung Research Center
Vancouver, British Columbia, Canada, V6Z 1Y6
Kelowna General Hospital
Kelowna, British Columbia, Canada, V1YE4
Canada, Newfoundland and Labrador
The Health Care Corporation of St. John's-Eastern Health
St. John's, Newfoundland and Labrador, Canada, A1B 3V6
Canada, Ontario
Toronto General Hospital-Rosedale Medical Center PFT Lab
Toronto, Ontario, Canada, M4X 1W4
Lawson Health Research Institute
London, Ontario, Canada, N6A 4G5
St. Joseph's Healthcare Hamilton
Hamilton, Ontario, Canada, L8N 4A6
Canada, Quebec
Institut de Cardiologie et de Pneumologie de l'Universite Laval
Ste-Foy, Quebec, Canada, G1V 4G5
Croatia
University Hospital for Lung Disease "Jordanovac"
Zagreb, Croatia, 10000
Czech Republic
University Hospital Na Bulovce
Praha 8, Czech Republic, 180 81
University Hospital-Department of Respiratory Disease-IP Pavlova
Olomouc, Czech Republic, 77520
Thomayer Faculty Hospital Prague-Dept of Respiratory Disease
Praha 4, Czech Republic, 140 59
France
Hopital Louis Pradel
Bron, France, 69677
Hopital Avicenne
Bobigny, France, 93009
HYLAB, Clinique du Mail
Grenoble, France, 38100
CHU Hôpital Arnaud de Villeneuve
Montpellier, France, 34295
Hopital Bichat
Paris, France, 75877
CHRU de Lille-Hopital Albert Calmette
Lille Cedex, France, 59037
Germany
SKlinikum der Universität München Medizinische Klinik und Poliklinik 1 - Grosshadern
Munich, Germany, 81377
Justus-Liebig-Universitat Giessen-Zentrum für Innere Medizin
Giessen, Germany, 35392
Fachkrankenhaus Coswig; Centre for Pumonology and Thoracic Surgery
Coswig, Germany
Ruhrlandklinik Pneumologie/Allergologie
Essen, Germany, 45239
HELIOS Klinikum Emil von Behring
Berlin, Germany, D-14165
Fachklinik fur Lungenerkrankungen
Immenhausen, Germany
Thoraxklinik Heidelberg GmbH
Heidelberg, Germany, 01640
Lungenfachklinik Immenhausen; Pneumologische Lehrklinik der Universität Göttingen
Immenhausen, Germany
Klinik Löwenstein GmbH-Medizinische Klinik 1 Pnemologie Kardiologie
Löwenstein, Germany, 74245
Klinik Donaustauf-Zentrum für Pneumologie
Donaustauf, Germany, 93093
Ireland
Mater Misicordiae University Hospital
Dublin, Ireland, 7
Israel
Sheba Medical Centre-Pulmonology Institute
Tel-Hashomer, Israel, 52621
Kaplan Medical Centre-Pulmonary Istitute
Rehovot, Israel, 76100
Tel-Aviv Sourasky Medical Centre-Institute of Pulmonary & Allergy Diseases
Tel-Aviv, Israel, 64239
Hadassah medical Centrte: Ein Karem-Institue of Pulmonology
Jerusalem, Israel, 91120
Rabin Medical Centre-Beilinson Campus-Pulmonary Istitute
Petach Tikvah, Israel, 49100
Rambam Medical Centre-Div. for Pulmonary Disease
Haifa, Israel, 31096
Pulmonary Institute-Rabin Medical Center: Beilinson Campus
Petach Tikvah, Israel, 49100
Italy
Azienda Ospedaliero-Universitaria San Luigi Gonzaga
Orbassano (Torino), Italy, 10043
Azienda Ospedaliera di Padova - Immunologia Clinica
Padova, Italy, 35128
Azienda Sanitaria di Forli-Presidio Ospedaliero Stabilimento
Forli, Italy, 47100
Pneumologia ISMETT
Palermo, Italy, 90127
Ospedale San Giuseppe Milanocuore, Unita Operativa di Pneumologia
Milan, Italy, 20123
University degli Studi Siena, Policlinico le Scotte
Siena, Italy, 53100
Japan, Aichi
Tosei General Hospital
Seto, Aichi, Japan, 489-8642
Japan, Hyogo
Himeji medical center
Himeji, Hyogo, Japan, 670-8520
Japan, Kanagawa
Kanagawa Cardiovascular Respiratory Center
Yokohama, Kanagawa, Japan, 236-0051
Japan, Nara
Tenri Hospital
Tenri, Nara, Japan, 632-8552
Japan, Osaka
Kinki - Chuo Chest Medical Center
Sakai, Osaka, Japan, 591-8555
Korea, Republic of
Samsung Medical Center
Seoul, Korea, Republic of, 135-710
Asan Medical Center
Seoul, Korea, Republic of, 138-736
Gil Medical Centre, Gachon University
Incheon, Korea, Republic of, 405-760
Seoul National University Hospital
Seoul, Korea, Republic of, 110-744
Soon Chun Hyang University Bucheon Hospital
Seoul, Korea, Republic of, 420-767
Netherlands
Academisch Medisch Centrum Amsterdam
Amsterdam, Netherlands, 1105 AZ
Serbia
Institut za Plucne bolest 1 TBC Klinickog Centra Srbije
Belgrade, Serbia, 11000
Institut za Plucne bolesti Vojodine
Sremska Kamenica, Serbia, 21204
Spain
Hospital La Princesa
Madrid, Spain, 28006
Hospital General de Valencia
Valencia, Spain, 46014
Hospital Universitario Ramon y Cajal
Madrid, Spain, 28034
Hospital General Vall d'Hebron-Neumologia
Barcelona, Spain, 08035
Hospital Universitario Dr. Peset
Valencia, Spain, 46017
Hospital Clinico San Carlos
Madrid, Spain, 28040
Hospital Clinic Barcelona (Pneumology Service)
Barcelona, Spain, 08036
Switzerland
Inselspital Bern-Div of Pulmonary Medicine
Bern, Switzerland, 3010
University Hospital Basel-Div of Pneumology
Basel, Switzerland, 4031
University Hospital Zurich-Clinic for Pneumology & Lung Transplant Program
Zurich, Switzerland, 8091
United Kingdom
Wythenshawe Hospital
Manchester, United Kingdom, M23 9LT
Southmead Hospital
Bristol, United Kingdom, BS105NB
Royal Brompton Hospital
London, United Kingdom
Papworth Hospital
Cambridgeshire, United Kingdom, CB23 3RE
Aberdeen Royal Infirmary
Aberdeen, United Kingdom, AB252ZN
Sponsors and Collaborators
Actelion
Investigators
Study Chair: Isabelle Leconte Actelion
  More Information

No publications provided

Responsible Party: Actelion ( Sponsor )
Study ID Numbers: AC-052-322
Study First Received: February 12, 2008
Last Updated: October 14, 2009
ClinicalTrials.gov Identifier: NCT00631475     History of Changes
Health Authority: United States: Food and Drug Administration;   United States: Institutional Review Board

Keywords provided by Actelion:
bosentan
Tracleer
Actelion
BUILD 3
Idiopathic Pulmonary Fibrosis
Interstitial Lung Disease

Additional relevant MeSH terms:
Lung Diseases, Interstitial
Pathologic Processes
Respiratory Tract Diseases
Fibrosis
Therapeutic Uses
Lung Diseases
Cardiovascular Agents
Antihypertensive Agents
Pulmonary Fibrosis
Pharmacologic Actions
Bosentan

ClinicalTrials.gov processed this record on November 27, 2009